High lymphocyte count and bleeding risk in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors
{{output}}
Bruton's tyrosine kinase inhibitors (BTKi) are being increasingly used to treat patients with chronic lymphocytic leukemia (CLL). Pathological bleeding is a well-known side effect of BTKi but identifying its predictors remains a challenge. This retrospective ... ...
